Kwality Pharmaceutical

Amritsar, India Founded: 1983 • Age: 43 yrs Listed
Developer and manufacturer of generic tablets, capsules, syrup, and injectables
Request Access
Report Incorrect Data
Page last updated

About Kwality Pharmaceutical

Kwality Pharmaceutical is a publicly listed company based in Amritsar (India) founded in 1983. Developer and manufacturer of generic tablets, capsules, syrup, and injectables. The company has 997 employees. Its chief executive, as recorded, is Ramesh Arora. Its Indian entity Kwality Pharmaceuticals Limited reported revenue of ₹506 Cr. Kwality Pharmaceutical offers products and services including Generic Drugs and Injectables. Its focus areas include Traditional Pharmaceuticals, Generics and Diversified.

Company details

Founded in 1983 in Amritsar, India, Kwality Pharmaceutical operates in the generics sector. Tablets, capsules, syrups, sterile powders for injections, and small-volume injectables are manufactured across therapeutic areas such as antibiotics, analgesics, gastrointestinal treatments, antivirals, and anti-inflammatories. Production occurs in a facility equipped with modern technology and supported by a skilled workforce.

  • Headquarters Amritsar, India
  • Employees 997
  • Stage Public
  • Sectors
    Healthcare
  • Email
    ••••••••
  • Phone
    •••• ••••
  • Website kwalitypharma.com
  • Social LinkedIn Facebook Instagram
  • Legal Name Kwality Pharmaceuticals Ltd
Operational Areas
Healthcare → Traditional Health & Nutrition
Key Metrics
  • Market Cap
    ₹3,735 Cr

    KPL · NSE

  • Share Price
    ₹3,696.70

    +2.70% today

  • Revenue
    ₹503 Cr

    FY 2025-26 · +35.9% YoY

  • EBITDA
    ₹117 Cr

    Margin 23.3%

  • Net Profit
    ₹67.45 Cr

    FY 2025-26 · +69.4% YoY

  • P/E (TTM)
    44.0x

    P/B 10.9x

  • ROE
    22.7%

    ROCE 23.8%

  • Debt / Equity
    0.41

    Interest cover 11.2x

  • Employee Count
    997

Products & Services of Kwality Pharmaceutical

Kwality Pharmaceutical offers a comprehensive portfolio of products and services, including Generic Drugs and Injectables.

Generic Drugs
Pharmaceutical Products

Generic drugs are produced for therapies like critical care and anti-infectives.

Injectables
Pharmaceutical Products

Injectables are manufactured, including lyophilized injections and vials for various treatments.

Board of directors of Kwality Pharmaceuticals Limited (Kwality Pharmaceutical)

Kwality Pharmaceuticals Limited is the primary company behind Kwality Pharmaceutical. The board of Kwality Pharmaceuticals Limited currently have 10 directors; the longest-serving is Ramesh Kumar, appointed in 1983. 10 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Ramesh Kumar
DIN 00462656
Managing Director04 May 198343 yrs 5 moKwality Pharmaceuticals Limited
Ajay Kumar Arora
DIN 00462664
Whole-time director01 Aug 199531 yrs 2 moKwality Pharmaceuticals Limited
Geeta Arora
DIN 03155615
Whole-time director01 Oct 201016 yrsKwality Pharmaceuticals Limited
Anju Arora
DIN 03155641
Whole-time director01 Oct 201016 yrsKwality Pharmaceuticals Limited
Aditya Arora
DIN 07320410
Whole-time director22 Oct 201511 yrsKwality Pharmaceuticals Limited
Prashanth Vellanki
DIN 05182633
Director16 Mar 20233 yrs 7 moKwality Pharmaceuticals Limited
Vinod Kumar Sharma
DIN 08502519
Director26 Jul 20251 yr 3 moKwality Pharmaceuticals Limited
Preetmohinder Singh Bedi
DIN 11452004
Director01 Jan 20269 moKwality Pharmaceuticals Limited
Bhavesh Mahajan
DIN 09614108
Director28 Jan 20268 moKwality Pharmaceuticals Limited
Swanith Kapoor
DIN 11662482
Director02 Jun 20264 moKwality Pharmaceuticals Limited

People of Kwality Pharmaceutical

7 people are tracked at Kwality Pharmaceutical (2 in leadership, 5 in team); the tracked headcount is 997.

NameRoleGroup
Ramesh Arora
CEO & MDLeadership
S Saini
General Manager -corporate Human ResourcesLeadership
Bangaroju Haribabu
International Business DevelopmentTeam
Rajinder Singh
IT ManagerTeam
Saurabh Kumar Jha
Software DeveloperTeam
Arun Chauhan
Graphic DesignerTeam
Sonu Yadav
Software DeveloperTeam
Premium access

Complete people profiles for Kwality Pharmaceutical

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Kwality Pharmaceutical

Kwality Pharmaceutical is a publicly listed company on the BSE with ticker symbol KPL in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date18 Jul 2016
  • Listed onBSE: 539997
  • Listed entityKwality Pharmaceuticals Ltd
  • Exchange sectorHealth technology
  • ISININE552U01010
  • Share price₹1,700.85 (-1.61% on the day) · 2026-05-11
  • Market capitalisation₹1,817 Cr
  • Price to earnings31.2
  • EPS (diluted, trailing year)₹54.49
  • Volume (last session)5,781
  • Analyst consensusNo rating

Financials of Kwality Pharmaceutical

Exchange-reported figures of Kwality Pharmaceuticals Limited, the listed company behind Kwality Pharmaceutical (NSE: KPL).

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹503 Cr
+35.9% YoY
EBITDA
₹117 Cr
+46.0% YoY
Profit After Tax
₹67.45 Cr
+69.4% YoY
Net Worth
₹332 Cr
+25.6% YoY
Total Assets
₹468 Cr
+24.7% YoY
Total Debt
₹130 Cr
+16.0% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue503370307251456262139
Revenue growth+35.9%+20.5%+22.4%-45.0%+74.1%+88.1%-
EBITDA11780.4059.2244.2017228.8614.22
EBITDA margin+23.3%+21.7%+19.3%+17.6%+37.6%+11.0%+10.2%
Profit before tax89.5054.1531.1025.5716221.2810.93
Net profit67.4539.8129.0931.5712015.178.25
Net profit margin+13.4%+10.8%+9.5%+12.6%+26.3%+5.8%+5.9%
EPS (₹)64.9038.4022.9318.67115.6414.608.02
Balance sheet
Total assets46837532129023511189.73
Net worth33226422420118161.1646.01
Total debt13011298.1290.2754.0141.2334.97
Cash & bank3.5914.765.947.3612.955.811.54
Net working capital28121216914412246.1342.74
Cash flow
Cash from operations17.0652.7242.9841.3860.6026.716.16
Cash from investing(34.91)(28.52)(26.40)(48.44)(62.93)(23.20)(17.80)
Cash from financing7.04(14.44)(17.40)0.995.660.7711.77
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue16215712311111111684.4190.03
Revenue growth (YoY)+45.6%+35.8%+46.2%+23.4%+39.2%---
Other income0.621.060.530.900.380.770.650.22
EBITDA41.0238.7629.1225.3524.1825.8917.5019.66
EBITDA margin+25.3%+24.7%+23.6%+22.8%+21.7%+22.4%+20.7%+21.8%
Depreciation4.995.264.824.964.765.094.564.62
Interest2.662.892.482.842.762.492.202.71
Profit before tax33.9931.6722.3518.4517.0419.0811.3912.55
Tax8.366.356.354.335.114.592.874.10
Net profit25.6325.3216.0014.1211.9314.498.528.45
EPS (₹)24.6924.3915.4213.6011.4913.958.218.15
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue503370307251456262139
Revenue growth+35.9%+20.5%+22.4%-45.0%+74.4%+88.6%-
EBITDA11780.4559.5344.3417229.2614.13
EBITDA margin+23.3%+21.7%+19.4%+17.7%+37.7%+11.2%+10.2%
Profit before tax89.5054.2331.4625.7516221.7911.14
Net profit67.4539.8529.2931.6912015.428.35
Net profit margin+13.4%+10.8%+9.5%+12.6%+26.3%+5.9%+6.0%
EPS (₹)64.9038.4423.1118.76115.6914.868.13
Balance sheet
Total assets47137932429323711491.86
Net worth33326622620218362.5147.10
Total debt13011298.1290.2754.0141.2334.97
Cash & bank3.5414.295.046.0910.875.131.15
Net working capital28221317014512246.2542.38
Cash flow
Cash from operations17.0052.7743.3542.1959.2426.365.63
Cash from investing(34.91)(28.13)(26.40)(48.44)(62.98)(23.20)(17.13)
Cash from financing7.04(14.44)(17.40)0.995.660.8312.36
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue16215712311111111684.4190.03
Revenue growth (YoY)+45.6%+35.6%+46.2%+23.6%+39.2%---
Other income0.621.060.530.900.380.770.650.22
Total expenses12111894.3285.9687.2989.7866.9070.35
EBITDA41.0238.7429.1225.3524.1925.9017.5119.68
EBITDA margin+25.3%+24.7%+23.6%+22.8%+21.7%+22.4%+20.7%+21.9%
Depreciation4.995.264.824.964.765.084.554.61
Interest2.662.892.482.842.762.492.202.71
Profit before tax33.9931.6522.3518.4517.0519.1011.4112.58
Tax8.366.356.354.335.114.592.874.10

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 28 Oct 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue16215712311111111684.4190.03
Revenue growth (YoY)+45.6%+35.8%+46.2%+23.4%+39.2%---
Other income0.621.060.530.900.380.770.650.22
EBITDA41.0238.7629.1225.3524.1825.8917.5019.66
EBITDA margin+25.3%+24.7%+23.6%+22.8%+21.7%+22.4%+20.7%+21.8%
Depreciation4.995.264.824.964.765.094.564.62
Interest2.662.892.482.842.762.492.202.71
Profit before tax33.9931.6722.3518.4517.0419.0811.3912.55
Tax8.366.356.354.335.114.592.874.10
Net profit25.6325.3216.0014.1211.9314.498.528.45
EPS (₹)24.6924.3915.4213.6011.4913.958.218.15
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue503370307251456262139
Revenue growth+35.9%+20.5%+22.4%-45.0%+74.1%+88.1%-
Other income2.861.921.832.943.511.593.66
Total expenses386290248207285233125
Employee cost51.1041.2630.4628.1618.8014.7010.92
EBITDA11780.4059.2244.2017228.8614.22
EBITDA margin+23.3%+21.7%+19.3%+17.6%+37.6%+11.0%+10.2%
Depreciation19.8118.2919.5614.9610.696.494.43
Interest10.979.8810.396.612.922.682.52
Profit before tax89.5054.1531.1025.5716221.2810.93
Tax22.1414.347.486.3041.626.382.71
Net profit67.4539.8129.0931.5712015.178.25
Net profit margin+13.4%+10.8%+9.5%+12.6%+26.3%+5.8%+5.9%
EPS (₹)64.9038.4022.9318.67115.6414.608.02
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital10.3810.3810.3810.3810.3810.3810.38
Reserves & surplus32125421419017150.7835.63
Shareholders' funds (net worth)33226422420118161.1646.01
Minority interest(1.67)(1.65)(1.63)(1.45)(1.35)(1.30)(1.04)
Secured loans13011298.1290.1553.3132.7229.42
Unsecured loans0.000.000.000.120.708.515.55
Total debt13011298.1290.2754.0141.2334.97
Total liabilities46837532129023511189.73
Assets
Gross block26123220717012882.2262.60
Net block15614613912091.7456.5342.69
Capital work in progress17.010.000.0014.2912.152.890.00
Investments0.000.000.000.000.005.173.99
Inventories78.2583.4778.3993.3753.3617.3622.42
Sundry debtors28015411471.6969.1335.7130.33
Cash & bank balances3.5914.765.947.3612.955.811.54
Loans & advances43.7831.2643.9741.8392.3742.5831.41
Total current assets40628424321422810185.70
Total current liabilities12472.1873.2970.0310655.3342.96
Net working capital28121216914412246.1342.74
Total assets46837532129023511189.73
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash12.022.263.079.135.811.541.40
Net cash from operating activities17.0652.7242.9841.3860.6026.716.16
Net cash from investing activities(34.91)(28.52)(26.40)(48.44)(62.93)(23.20)(17.80)
Net cash from financing activities7.04(14.44)(17.40)0.995.660.7711.77
Net change in cash(10.81)9.76(0.81)(6.07)3.334.270.14
Closing cash3.5914.765.947.3612.955.811.54
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+35.9%+20.5%+22.4%-45.0%+74.1%+88.1%-
EBITDA growth+46.0%+35.8%+34.0%-74.3%+494.8%+103.0%-
PBT growth+65.3%+74.1%+21.6%-84.2%+659.3%+94.7%+0.1%
Net income growth+69.4%+36.9%-7.9%-73.7%+691.0%+83.9%-
Revenue CAGR (3Y)+26.1%-6.7%+5.4%+21.7%+40.0%+24.0%+12.3%
EBITDA CAGR (3Y)+38.5%-22.3%+27.1%+45.9%+121.9%+35.2%+16.9%
Profitability & leverage
Net income margin+13.4%+10.8%+7.7%+7.7%+26.3%+5.7%+5.9%
Return on capital employed+23.8%+18.4%+15.9%+18.5%+94.9%+23.8%+17.3%
Return on net worth+22.7%+16.4%+13.7%+16.6%+99.7%+28.2%+20.1%
Debt / equity0.410.430.450.380.400.720.78
Long-term debt / equity0.070.070.110.130.160.270.22
Interest cover11.2415.9126.2022.611.8111.9825.74
Efficiency & per share
Fixed asset turnover2.051.701.641.694.373.662.56
Inventory turnover6.224.573.583.4212.9013.178.27
Debtors turnover2.322.763.303.578.707.934.05
EPS (₹)64.9038.4022.9318.67115.6414.608.02
Dividend per share (₹)0.000.000.000.000.000.000.00
Book value per share (₹)318.80253.70215.31192.48173.8158.1643.57
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue16215712311111111684.4190.03
Revenue growth (YoY)+45.6%+35.6%+46.2%+23.6%+39.2%---
Other income0.621.060.530.900.380.770.650.22
Total expenses12111894.3285.9687.2989.7866.9070.35
EBITDA41.0238.7429.1225.3524.1925.9017.5119.68
EBITDA margin+25.3%+24.7%+23.6%+22.8%+21.7%+22.4%+20.7%+21.9%
Depreciation4.995.264.824.964.765.084.554.61
Interest2.662.892.482.842.762.492.202.71
Profit before tax33.9931.6522.3518.4517.0519.1011.4112.58
Tax8.366.356.354.335.114.592.874.10
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue503370307251456262139
Revenue growth+35.9%+20.5%+22.4%-45.0%+74.4%+88.6%-
Other income2.861.921.832.943.511.593.92
Total expenses386290248207284232125
Employee cost51.1041.2430.4328.1018.7414.4810.68
EBITDA11780.4559.5344.3417229.2614.13
EBITDA margin+23.3%+21.7%+19.4%+17.7%+37.7%+11.2%+10.2%
Depreciation19.7918.2619.5114.9210.646.444.39
Interest10.979.8810.396.612.922.622.52
Profit before tax89.5054.2331.4625.7516221.7911.14
Tax22.1414.347.486.3041.626.382.71
Net profit67.4539.8529.2931.6912015.428.35
Net profit margin+13.4%+10.8%+9.5%+12.6%+26.3%+5.9%+6.0%
EPS (₹)64.9038.4423.1118.76115.6914.868.13
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital10.3810.3810.3810.3810.3810.3810.38
Reserves & surplus32325521619217252.1336.72
Shareholders' funds (net worth)33326622620218362.5147.10
Secured loans13011298.1290.1553.3132.7229.42
Unsecured loans0.000.000.000.120.708.515.55
Total debt13011298.1290.2754.0141.2334.97
Total liabilities47137932429323711491.86
Assets
Gross block25923020516912780.7961.18
Net block15414413812090.7755.5241.63
Capital work in progress17.010.000.0014.2912.152.890.00
Investments3.553.553.553.553.558.727.54
Inventories78.2583.4778.3993.3753.3617.3622.42
Sundry debtors28115611673.2970.7137.7830.35
Cash & bank balances3.5414.295.046.0910.875.131.15
Loans & advances43.7831.2643.9741.8392.3741.1731.28
Total current assets40728524321522710185.20
Total current liabilities12472.1873.2970.0210555.1942.82
Net working capital28221317014512246.2542.38
Total assets47137932429323711491.86
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash11.551.351.807.065.131.150.28
Net cash from operating activities17.0052.7743.3542.1959.2426.365.63
Net cash from investing activities(34.91)(28.13)(26.40)(48.44)(62.98)(23.20)(17.13)
Net cash from financing activities7.04(14.44)(17.40)0.995.660.8312.36
Net change in cash(10.87)10.20(0.45)(5.26)1.933.990.87
Closing cash3.5414.295.046.0910.875.131.15
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+35.9%+20.5%+22.4%-45.0%+74.4%+88.6%-
EBITDA growth+45.9%+35.1%+34.3%-74.2%+486.9%+107.1%-
PBT growth+65.0%+72.4%+22.2%-84.1%+642.0%+95.6%+2.2%
Net income growth+69.3%+36.1%-7.6%-73.6%+678.6%+84.7%-
Revenue CAGR (3Y)+26.1%-6.7%+5.5%+21.9%+40.3%+24.1%+13.3%
EBITDA CAGR (3Y)+38.3%-22.3%+26.7%+46.4%+124.1%+36.5%+18.2%
Profitability & leverage
Net income margin+13.4%+10.8%+7.8%+7.8%+26.3%+5.9%+6.1%
Return on capital employed+23.7%+18.3%+15.9%+18.5%+94.2%+24.0%+17.3%
Return on net worth+22.5%+16.3%+13.7%+16.6%+98.6%+28.6%+20.0%
Debt / equity0.410.430.440.380.390.710.75
Long-term debt / equity0.070.070.110.120.160.260.20
Interest cover11.2415.8925.9622.471.8111.4825.87
Efficiency & per share
Fixed asset turnover2.061.711.651.714.433.732.62
Inventory turnover6.224.573.583.4212.9013.158.24
Debtors turnover2.302.723.253.498.417.684.01
EPS (₹)64.9038.4423.1118.76115.6914.868.13
Dividend per share (₹)0.000.000.000.000.000.000.00
Book value per share (₹)320.51255.43216.98193.93175.1759.4744.62

Web traffic of Kwality Pharmaceutical

The website of Kwality Pharmaceutical (kwalitypharma.com) receives about 5.3K visits a month.

  • Monthly visits
    5.3K

    ▼ 35.7% vs previous month

Top companies in Traditional Health & Nutrition

3 companies that operate in the same segment as Kwality Pharmaceutical (Traditional Health & Nutrition) in India, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Inventia Healthcare
Oral solid drug delivery systems are manufactured and developed.
1985Mumbai, Maharashtra, IndiaUSD 42.49 MUSD 89.42 M962
Strides Pharma Science
Generic, semi-solid, and liquid dosage forms are manufactured.
1990Bengaluru, Karnataka, IndiaUSD 508.93 M5,180
Sun Pharma
Specialty generic pharmaceuticals and APIs are manufactured and marketed.
1983Mumbai, Maharashtra, IndiaUSD 6.21 B25,870
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Kwality Pharmaceutical

Kwality Pharmaceuticals Completes Phase 1 BE Studies For Three Molecules
Reuters • 7 months ago
KPL: Q3 and 9MFY26 saw robust revenue and profit growth, driven by regulated market expansion
Quartr • 8 months ago
KPL: Q3 FY26 revenue up 46% YoY, PAT up 78%, with robust international expansion and margin gains
Quartr • 8 months ago
Kwality Pharmaceuticals Ltd Dec-Quarter Consol Net Profit 160.1 Million Rupees
Reuters • 8 months ago
KPL: Strong H1 FY26 growth, improved margins, and confident outlook for exceeding FY26 targets
Quartr • 11 months ago
Kwality Pharmaceuticals Sept-Qtr Consol Net Profit 141.2 Mln Rupees
Reuters • 11 months ago
R&B Denims Ltd leads losers in 'B' group | Capital Market News - Business Standard
Business Standard • 1 year ago
KPL: Q1 FY26 saw 40% revenue growth and 43% profit rise, with strong global expansion momentum
Quartr • 1 year ago
Kwality Pharmaceuticals consolidated net profit rises 42.70% in the June 2025 quarter | Capital Market News - Business Standard
Business Standard • 1 year ago
Kwality Pharmaceuticals consolidated net profit rises 232.34% in the March 2025 quarter | Capital Market News - Business Standard
Business Standard • 1 year ago
Premium access

Complete news archive for Kwality Pharmaceutical

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Kwality Pharmaceutical

Kwality Pharmaceutical was founded in 1983.

Kwality Pharmaceutical is headquartered in Amritsar, India. It is registered at Amritsar, Punjab, India.

Ramesh Arora is the CEO of Kwality Pharmaceutical, as recorded in our data.

Kwality Pharmaceutical has 997 employees.

The primary company behind Kwality Pharmaceutical, Kwality Pharmaceuticals Limited, reported revenue of ₹506 Cr for FY 2026, up 36% year on year.

Founded in 1983 in Amritsar, India, Kwality Pharmaceutical operates in the generics sector. Tablets, capsules, syrups, sterile powders for injections, and small-volume injectables are manufactured across therapeutic areas such as antibiotics, analgesics, gastrointestinal treatments, antivirals, and anti-inflammatories. Production occurs in a facility equipped with modern technology and supported by a skilled workforce.

Kwality Pharmaceutical offers Generic Drugs and Injectables.

Yes, Kwality Pharmaceutical is publicly traded on BSE under the ticker symbol KPL.

Kwality Pharmaceutical operates through Kwality Pharmaceuticals Limited.

The legal entities of Kwality Pharmaceutical currently have 11 directors, including Ajay Kumar Arora, Geeta Arora, Anju Arora and others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available